Targeting bromodomains: epigenetic readers of lysine acetylation

  title={Targeting bromodomains: epigenetic readers of lysine acetylation},
  author={Panagis Filippakopoulos and Stefan Knapp},
  journal={Nature Reviews Drug Discovery},
Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases. Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes. These complexes can then initiate transcriptional programmes that result in phenotypic changes. The… 

Bromodomain Histone Readers and Cancer.

The Bromodomain: A New Target in Emerging Epigenetic Medicine.

The bromodomain (BrD) is a conserved protein modular domain found in many chromatin- and transcription-associated proteins that has the ability to recognize acetylated lysine residues and plays a vital role in many acetylation-mediated protein-protein interactions in the cell.

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy

The mechanisms of action of various BET inhibitors and the prospects for their clinical use as cancer therapeutics are discussed, following the demonstration that thienotriazolodiazepine small molecules effectively inhibit BET.

Bromodomain biology and drug discovery

The current understanding of bromodomain biology is highlighted, and the latest development of small-molecule inhibitors that target these protein domains as emerging therapies for cancer and inflammatory disorders are discussed.

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability

It is found that most BET missense mutations localize to peripheral residues in the two terminal helices, suggesting new interactions and an alternative network of protein-protein interconnection as a consequence of single amino acid substitution.

Bromodomain inhibitors and cancer therapy: From structures to applications

The structures and mechanisms associated with Bromodomain and Extra-Terminal motif (BET) inhibitors and non-BET inhibitors, their current status of development, and their promising role as anti-cancer agents are described.

Bromodomains: A novel target for the anticancer therapy.

The Bromodomain as the Acetyl-Lysine Binding Domain in Gene Transcription

This chapter takes a closer look at the structure and functions of the BrD, as well as its interaction with other chromatin-associated modules and its overall role in disease biology.



Bromodomains as therapeutic targets

It is likely that BRDs will emerge alongside HATs and HDACs as interesting targets for drug development for the large number of diseases that are caused by aberrant acetylation of lysine residues.

4-Acyl pyrroles: mimicking acetylated lysines in histone code reading.

BRD4 has been characterized as a key determinant in acute myeloid leukemia, multiple myeloma, Burkitt s lymphoma, NUT midline carcinoma, colon cancer, and inflammatory disease, and small molecules that inhibit BRD4 have potential as antiinflammatory, antiviral, and anticancer agents.

Structure and ligand of a histone acetyltransferase bromodomain

The solution structure of the bromodomain of the HAT co-activator P/CAF (p300/CBP-associated factor) reveals an unusual left-handed up-and-down four-helix bundle, and it is shown by a combination of structural and site-directed mutagenesis studies that bromidomains can interact specifically with acetylated lysine, making them the first known protein modules to do so.

Naphthyridines as Novel BET Family Bromodomain Inhibitors

1,5‐naphthyridine derivatives are reported as potent inhibitors of the BET bromodomain family with good cell activity and oral pharmacokinetic parameters and the best compounds were progressed in a mouse model of inflammation and exhibited dose‐dependent anti‐inflammatory pharmacology.

Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites

This represents the first analysis of this type for the bromodomain family and can prove useful in the discovery of inhibitors, particularly for anticipating screening hit rates, identifying inhibitors that can be explored for lead hopping approaches, and selecting proteins for selectivity screening.

Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit

The discovery and structure–activity relationship (SAR) of a novel, small-molecule chemical probe for BET family inhibition that was identified through the application of structure-based fragment assessment and optimization techniques has yielded a potent, selective compound with cell-based activity (PFI-1) that may further add to the understanding of BET family function within the bromodomains.

3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands

Using X-ray crystallographic analysis, the interactions responsible for the activity and selectivity of 4-substituted 3,5-dimethylisoxazoles against a selection of phylogenetically diverse bromodomains are determined and compound 4d is developed, which has IC50 values of <5 μM for the b romodomain-containing proteins BRD2(1) and BRD4(1).

BET domain co-regulators in obesity, inflammation and cancer

Small molecules that inhibit bromodomain and extraterminal (BET) proteins have been described and the implications for small molecule epigenetic targeting of chromatin networks in cancer are discussed.

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

A proteomic-scale analysis of protein acetylation suggests that it is an important biological regulatory mechanism and the regulatory scope of lysine acetylations is broad and comparable with that of other major posttranslational modifications.